Yvonne Aratyn-Schaus
Overview
Explore the profile of Yvonne Aratyn-Schaus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1089
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arnaoutova I, Aratyn-Schaus Y, Zhang L, Packer M, Chen H, Lee C, et al.
Nat Commun
. 2024 Nov;
15(1):9729.
PMID: 39523369
Glycogen storage disease type-Ia patients, deficient in the G6PC1 gene encoding glucose-6-phosphatase-α, lack blood glucose control, resulting in life-threatening hypoglycemia. Here we show our humanized mouse model, huR83C, carrying the...
2.
Packer M, Chowdhary V, Lung G, Cheng L, Aratyn-Schaus Y, Leboeuf D, et al.
Mol Ther
. 2022 Feb;
30(4):1396-1406.
PMID: 35121111
Alpha-1 antitrypsin deficiency (AATD) is a rare autosomal codominant disease caused by mutations within the SERPINA1 gene. The most prevalent variant in patients is PiZ SERPINA1, containing a single G...
3.
Werder R, Kaserman J, Packer M, Lindstrom-Vautrin J, Villacorta-Martin C, Young L, et al.
Mol Ther
. 2021 Jul;
29(11):3219-3229.
PMID: 34217893
Alpha-1 antitrypsin deficiency (AATD) is most commonly caused by the Z mutation, a single-base substitution that leads to AAT protein misfolding and associated liver and lung disease. In this study,...
4.
Aratyn-Schaus Y, Ramanathan R
Bioanalysis
. 2016 Jul;
8(16):1645-62.
PMID: 27460981
Loratadine (LOR, Claritin(®)) is a long-acting antihistamine used to treat allergic rhinitis. The major active human metabolite, desloratadine (DL, Clarinex(®)), is extensively metabolized to 3-hydroxydesloratadine (3-OH-DL) (M40) and subsequently glucuronidated...
5.
Aratyn-Schaus Y, Pasqualini F, Yuan H, McCain M, Ye G, Sheehy S, et al.
J Cell Biol
. 2016 Feb;
212(4):389-97.
PMID: 26858266
The efficacy of cardiac cell therapy depends on the integration of existing and newly formed cardiomyocytes. Here, we developed a minimal in vitro model of this interface by engineering two...
6.
Pasqualini F, Sheehy S, Agarwal A, Aratyn-Schaus Y, Parker K
Stem Cell Reports
. 2015 Mar;
4(3):340-7.
PMID: 25733020
Structural phenotyping based on classical image feature detection has been adopted to elucidate the molecular mechanisms behind genetically or pharmacologically induced changes in cell morphology. Here, we developed a set...
7.
Sheehy S, Pasqualini F, Grosberg A, Park S, Aratyn-Schaus Y, Parker K
Stem Cell Reports
. 2014 Mar;
2(3):282-94.
PMID: 24672752
Advances in stem cell manufacturing methods have made it possible to produce stem cell-derived cardiac myocytes at industrial scales for in vitro muscle physiology research purposes. Although FDA-mandated quality assurance...
8.
Ye G, Aratyn-Schaus Y, Nesmith A, Pasqualini F, Alford P, Parker K
Integr Biol (Camb)
. 2014 Jan;
6(2):152-63.
PMID: 24406783
Vascular smooth muscle cells in muscular arteries are more elongated than those in elastic arteries. Previously, we reported changes in the contractility of engineered vascular smooth muscle tissue that appeared...
9.
McCain M, Lee H, Aratyn-Schaus Y, Kleber A, Parker K
Proc Natl Acad Sci U S A
. 2012 Jun;
109(25):9881-6.
PMID: 22675119
Adhesion between cardiac myocytes is essential for the heart to function as an electromechanical syncytium. Although cell-matrix and cell-cell adhesions reorganize during development and disease, the hierarchical cooperation between these...
10.
Stricker J, Aratyn-Schaus Y, Oakes P, Gardel M
Biophys J
. 2011 Jun;
100(12):2883-93.
PMID: 21689521
Focal adhesions (FAs) are the predominant mechanism by which cells mechanically couple to and exert traction forces on their extracellular matrix (ECM). It is widely presumed that FA size is...